MRNA advances around 10.5% after Phase 3 trial success for mRNA cancer vaccine with Merck

Traders Union
All News
Stocks
Moderna surges 10.59% today to $153.60

Highlights

Moderna and Merck reported their personalized mRNA cancer vaccine met primary and key secondary endpoints in the Phase 3 melanoma trial.
This is the first successful late-stage trial for an mRNA-based cancer therapy, showing clinically meaningful recurrence-free survival improvement after surgery.
Shares of Moderna rose 10.59% with strong bullish technical momentum, trading above key averages and resistance at $176.66, with an 80% probability of further upside.

Late-stage trial success shifts focus to approval and market entry

Moderna reported that its personalized mRNA cancer vaccine, intismeran autogene (V940/mRNA-4157), used alongside Merck’s Keytruda, met both primary and key secondary endpoints in the Phase 3 INTerpath-001 melanoma trial. This represents the first successful late-stage trial for an mRNA-based cancer therapy and demonstrated a clinically meaningful improvement in recurrence-free survival for high-risk melanoma patients following surgery. Following these results, attention is turning to regulatory pathways and potential commercialization.

Anton Kharitonov, expert at Traders Union, notes that Moderna’s rally is driven by positive clinical trial news but warns that market euphoria may be overextended. He sees overbought signals across multiple technical indicators and believes the surge could attract profit-taking or speculative unwind. Kharitonov highlights significant downside risk if $142.84 fails, as volatility remains high and sentiment can reverse quickly. He is cautious about sustainability, emphasizing that early regulatory optimism often fades if not converted into commercial progress. "Investors should remain vigilant and avoid chasing extended moves until new support levels are firmly established."

Viktoras Karapetjanc, expert at Traders Union, views Moderna’s breakthrough as transformative for the mRNA therapy industry. He highlights strong clinical outcomes and regulatory attention as key drivers for further upside. Karapetjanc believes the bullish structure remains intact with momentum favoring buyers, especially above $142.84. Growing institutional interest and successful trial data position MRNA for additional growth. "I see these developments laying the groundwork for continued advances and more opportunities as market conviction grows."

Parshwa Turakhiya, analyst, sees robust sentiment after Moderna’s strong rally. The decisive break above key averages and the upside gap suggest short-term traders remain in control. Turakhiya notes that overbought conditions could lead to range-bound action between $142.84 and $176.66 this week. With volatility elevated, sharp moves may occur if momentum stalls at resistance. "For nimble traders, this is a classic momentum setup but strict risk management is crucial with volatility this high."

Sustained bullish momentum as key resistance and support levels hold

Moderna is trading decisively above the 20-day ($76.73), 50-day ($69.39), and 200-day ($49.3) moving averages, confirming a strong bullish structure across all timeframes. With the stock positioned well above key trend levels, the focus shifts to the near-term ceiling at $176.66 as resistance and $142.84 as immediate support, with long-term momentum confirmed by the bullish alignment of MA-50 vs MA-200. Momentum remains robust, with both the Moving Average Convergence Divergence (MACD) and Average Directional Index (ADX) signaling buy conditions. The Relative Strength Index (RSI) at 68.82 is close to overbought, Commodity Channel Index (CCI) at 149.43 and Bull/Bear Power (BBP) at 42.57 both confirm the stock is overbought, and buyers clearly dominate intraday. The Awesome Oscillator (AO) also signals ongoing upward momentum. The stock rose $14.71 or 10.59%, opening with an upside gap of around $3.95 (2.84%) and trading near session highs. Intraday volatility stands at 9.67%, reflecting sustained strength toward the highs. Most momentum indicators confirm the forceful intraday move, with the Stochastic RSI as the only neutral signal.

Previously it was reported that Moderna shares experienced significant volatility despite a bullish technical setup, as investors weighed positive clinical results against ongoing selling pressure. The latest decisive breakout and sustained upward momentum not only reinforce the bullish outlook but also highlight $176.66 as the immediate resistance level to monitor for a potential continuation of gains.

Source of Data: MRNA Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.